Drug intelligence / Profile preview

NF-800

Development stage
Preclinical
Lead developer
Affilogic
Modality
Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

NF-800 is a novel diagnostic optical imaging probe composed of an anti-HER-2 Nanofitin conjugated to the near-infrared fluorophore IRDye800CW. Nanofitins are small (approx. 7 kDa), hyperstable antibody mimetics derived from the Sac7d protein of *Sulfolobus acidocaldarius*. NF-800 specifically targets the Human Epidermal Growth Factor Receptor 2 (HER-2) at an epitope distinct from those targeted by Trastuzumab and Pertuzumab, allowing for potential use in patients already receiving these standard-of-care antibodies. Due to its small size, NF-800 exhibits rapid biodistribution and renal clearance, providing high-contrast tumor imaging shortly after administration. It is intended for non-invasive detection of HER-2 expression, therapy monitoring, and fluorescence-guided surgery (FGS) to assist in the identification of tumor margins and lymph node involvement.

Other names
anti-HER-2 Nanofitin-IRDye800CWanti-HER2 Nanofitin-IRDye800CWanti-HER 2 Nanofitin-IRDye800CWNF-Cys-IRDye800CWNF-Cys-IRDye-800CWNF-Cys-IRDye 800CWNanofitin-IRDye800CWNanofitin-IRDye-800CWNanofitin-IRDye 800CW
02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on NF-800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NF-800.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call